Michigan MDHHS Technical Brief: Kratom Alkaloids, Health Effects, and Policy Landscape

Why it matters

State health agencies are publishing formal technical reviews to guide local policymakers and clinicians as kratom use rises. This Michigan MDHHS brief synthesizes the latest pharmacological, toxicological, and regulatory science into a single authoritative state document that is being used to inform legislation.

The big picture

The Michigan Department of Health and Human Services published this technical brief in late 2025 to comprehensively summarize kratom science for a policymaking audience. It covers the full range of kratom alkaloids — including mitragynine and 7-OH — their receptor binding profiles, drug interaction risks, and the range of reported adverse effects including neonatal abstinence syndrome.

Key findings

• Kratom contains more than 40 alkaloids; mitragynine typically makes up more than half of measured alkaloid content, while 7-OH is present in trace amounts in natural leaf but can be artificially concentrated in commercial products
• 7-OH has a mu-opioid receptor binding affinity greater than mitragynine and possibly greater than morphine, and can produce respiratory depression and opioid-like dependence
• Kratom alkaloids interact with CYP450 enzymes in the liver, raising risk of pharmacokinetic drug interactions with many commonly prescribed medications
• Heavy metal contamination (lead, arsenic exceeding FDA limits) has been documented in kratom products at typical consumer doses; adulteration with O-desmethyltramadol and salmonella have also been reported
• States with full kratom bans showed lower rates of poison center exposures and severe outcomes compared to states using consumer protection approaches or no regulation

What they say

The Michigan Department of Health and Human Services noted that "as kratom use rises, and concerns over kratom and its risks increase, legislatures across the country are debating the best ways to regulate its use. Ongoing policy debates reflect limited high quality evidence, highlighting the need for more rigorous, unbiased research to guide legislation."

Bottom line

This state health agency brief confirms kratom products can carry significant risks from alkaloid potency, drug interactions, and contamination — and documents that bans correlate with fewer severe outcomes than unregulated access.